ArrayPatch, a University College Cork spin-out that makes drug patches covered in tiny dissolving needles, raised €1.6m (about $1.9m) in the second close of its seed round, it announced on 5 November 2026.
The close was co-led by WakeUp Capital, an impact-focused venture firm, and Spark Venture Funding, with money from Dr Mark Ledwidge. It completes an oversubscribed seed round of €3.2m (about $3.7m).
Lakeside Capital, which led the first close, and DeepIE Ventures returned. Enterprise Ireland, the Boole Investment Syndicate and private investors also took part. Andrew Parish, a partner at WakeUp Capital, is joining the board. No valuation was disclosed.
“The successful completion of our €3.2 million seed round is an important milestone for ArrayPatch”Dr Waleed Faisal, Founder and CEO, ArrayPatch
What ArrayPatch makes
Microneedle patches deliver a drug through the skin using very small needles instead of an injection. ArrayPatch's DerMap platform makes the needles from the drug itself, without a polymer, which the company says allows a larger dose per patch. The platform can deliver both small-molecule drugs and peptides, the company said.
Its lead programme, GLP-DerMap, delivers a GLP-1 drug, for obesity and diabetes, and is in pre-clinical development. VIS-DerMap targets basal cell carcinoma, a common skin cancer, and is being developed with Research Ireland's Rinn Pharma & Biopharma centre, a collaboration that began earlier in 2026. ITZ-DerMap is aimed at fungal nail infections.
Who is behind it
The company was founded by chief executive Dr Waleed Faisal, a formulation scientist with a PhD in pharmaceutics from UCC, and was spun out of the university in 2024, according to Silicon Republic. Dr Neil Thomas was recently appointed chair.
"The successful completion of our €3.2 million seed round is an important milestone for ArrayPatch," Faisal said. "Our primary focus is now GLP-DerMap, where we believe our technology has the potential to offer a new, patient-friendly approach," he added. He said the company is also continuing its skin cancer and nail fungus programmes.
Silicon Republic described Spark as a venture crowdfunding platform and named Lakeside Capital and DeepIE Ventures as the round's existing leads.
Parish said the technology could make a significant global impact, and pointed to the environmental and safety problems linked to used needles from injections, which a dissolving patch would avoid. Silicon Republic described WakeUp Capital as an Irish climate-focused venture firm and Ledwidge as a professor at University College Dublin.
What the money is for
ArrayPatch said the funding will take its DerMap programmes towards first-in-human studies, starting with GLP-DerMap and VIS-DerMap. It pitches the GLP-1 patch as a patient-friendly alternative to injections for obesity and diabetes. It did not give a timeline.
ArrayPatch has not yet tested its patches in people. All three of its programmes are at the pre-clinical stage or earlier.
Besides the seed round, the company says it has secured significant non-dilutive funding and industry recognition, but it did not give figures. It did not disclose its headcount.
Company website: array-patch.com
